Immunovia AB (IMMVF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Immunovia AB $0.01, price $0.01, upside -15.0%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Immunovia AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual.
Show more
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Stock analysis
Immunovia AB (IMMVF) currently trades at $0.0100, while our model-based Fair Value estimate is $0.0085, 15.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Immunovia AB reported revenue of 683K SEK in FY2025 versus 844K SEK in FY2021, a compound −5.1%/yr. Reported net income was −146M SEK in FY2025.
Key figures
Market cap $13.5M · P/S ratio 17.1 · EPS (TTM) $−0.0400 · Return on equity −281% · Return on assets (EBIT) −164% · Revenue (TTM) 786K SEK · Revenue growth (YoY) +169% · Free cash flow −78.2M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −15%, IMMVF screens richer than that median.
Fair Value models
Bear $0.0085Fair Value $0.0085Bull $0.0085
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−26.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37,111.3% (2020) → −11,774.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−15.0% · Above median
Profitability
Return on assets−91.3% · Bottom 25%
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth169.1% · Top 25%
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Immunovia AB Fair Value". https://www.fairvalue-calculator.com/stock/IMMVF
Frequently asked questions
Is Immunovia AB (IMMVF) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0085 versus the last price from Sep 25, 2026 of $0.0100, about −15% upside (overvalued).
What is the fair value of IMMVF?
Our model-based fair value for Immunovia AB is $0.0085 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0100.
What is the quality score of IMMVF?
Immunovia AB has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunovia AB (IMMVF)?
Our model-based price target is the fair value of $0.0085 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Immunovia AB stock forecast for 2026?
Our models put fair value at $0.0085, about −15% upside versus the last price from Sep 25, 2026 of $0.0100 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Immunovia AB (IMMVF)?
Immunovia AB reported trailing-twelve-month revenue of about 786K SEK (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Immunovia AB (IMMVF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunovia AB it is $0.0085 per share (as of Sep 27, 2026), against a price of $0.0100. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Immunovia AB stock overvalued or undervalued in 2026?
As of Sep 27, 2026, IMMVF trades above its calculated fair value: price $0.0100, fair value $0.0085, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMMVF?
No. The price is what the market pays today ($0.0100); the fair value is what the company's own numbers justify ($0.0085). For Immunovia AB the two are $0.0015 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunovia AB worth?
The market values Immunovia AB at about $13.5M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0100; our models calculate a fair value of $0.0085 per share.
How solid is the balance sheet of Immunovia AB (IMMVF)?
Balance-sheet figures for Immunovia AB (as of Sep 27, 2026): return on equity −281.3%, debt of 0.51 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is IMMVF from its 52-week high?
Immunovia AB trades at $0.0100, about 81% below its 52-week high of $0.0521 and at the low of $0.0100 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0085 is for.
Which stocks are comparable to Immunovia AB?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunovia AB stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0100, calculated fair value $0.0085 (−15%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMMVF calculated?
We run Immunovia AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0085, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Immunovia AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunovia AB (IMMVF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0100. Our model-based fair value is $0.0085, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunovia AB right now?
The price sits above even our optimistic bull case ($0.0085). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Immunovia AB
How large is the market capitalisation of Immunovia AB (IMMVF)?
The market capitalisation of Immunovia AB is $13.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Immunovia AB (IMMVF)?
The price-to-sales ratio of Immunovia AB is 17.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Immunovia AB (IMMVF)?
Earnings per share at Immunovia AB are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Immunovia AB (IMMVF)?
The return on equity (ROE) of Immunovia AB is −281% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Immunovia AB (IMMVF)?
On an EBIT basis the return on assets of Immunovia AB is −164% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Immunovia AB (IMMVF)?
Revenue at Immunovia AB is growing +169% versus a year earlier (3y avg −15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Immunovia AB (IMMVF) generate?
The free cash flow of Immunovia AB is −78.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Immunovia AB (IMMVF) hold?
Immunovia AB holds more cash than debt, 76.4M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Immunovia AB in the live analysis
One click puts Immunovia AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026